COMMUNIQUÉS West-GlobeNewswire

Annual General Meeting of Ipsen S.A. held on 13 May 2026
13/05/2026
Annual General Meeting of Ipsen S.A. held on 13 May 2026 All the resolutions submitted to the shareholders’ vote have been adopted PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announces today that the [...]
Ipsen S.A. – Evolution de la composition du Conseil d’administration
13/05/2026
Ipsen S.A. – Evolution de la composition du Conseil d’administration PARIS, FRANCE, 13 MAI 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui que Madame Karen Witts a remis sa démission de son mandat d’ [...]
Ipsen S.A. – Evolution of the composition of the Board of Directors
13/05/2026
Ipsen S.A. – Evolution of the composition of the Board of Directors PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Mrs. Karen Witts has resigned from her position as a Director of [...]
JavaTide Claims Evaluated: Investigating the Java Tide Ingredients for Purity and Potency
13/05/2026
JavaTide Prebiotic and Probiotic Weight Loss Support: Chicory Root Inulin, Resistant Starch, and Akkermansia muciniphila for Gut Health and Metabolism Explained Largo, FL, May 13, 2026 (GLOBE NEWSWIRE) -- These [...]
AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2025 et présente un point sur ses activités
13/05/2026
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS ANNUELS AU 31 DECEMBRE 2025 ET LES EVENEMENTS CLEFS DE LA PERIODE Situation financière et corporate Déficit opérationnel de 3,8 millions d’euros au 31 [...]
AB Science reports its revenues for the year 2025 and provides an update on its activities
13/05/2026
PRESS RELEASE AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Financial and corporate position Operating loss of €3.8 million as of 31 December 2025, down 38% [...]
Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations
13/05/2026
Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment of hypertrophic [...]
MAPS Announces Dates for Psychedelic Science 2027; Early Bird Registrations Now Open
13/05/2026
Early bird registration is now open for Psychedelic Science 2027, taking place May 3–7, 2027, in Denver, Colorado. Early bird pricing offers discounted registration in limited quantities to the world’s leading [...]
Vicarious Surgical Demonstrates Sustained System Performance and Complex Hernia Procedure Workflows in Pre-Clinical Setting
13/05/2026
Company Remains on Track For Design Freeze by End of Year 2026 WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform [...]
ONWARD Medical Announces Results of the 2026 Annual General Meeting of Shareholders
13/05/2026
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, the Netherlands, May 13, 2026 [...]
EUROAPI statement regarding the Brindisi site
13/05/2026
Press Release Paris – May 13, 2026 – EUROAPI takes note of local media reports regarding its Brindisi site. As previously communicated, the review of strategic options for certain industrial assets is progressing in [...]
Information d’EUROAPI à propos du site de Brindisi
13/05/2026
Communiqué de presse Paris – Le 13 mai 2026 - EUROAPI prend note d’articles de presse locaux relatifs à son site de Brindisi. Comme indiqué précédemment, l’examen des options stratégiques concernant certains actifs [...]
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
13/05/2026
Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications MELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative [...]
Eric Palmer Joins AMN Healthcare Board of Directors
13/05/2026
DALLAS, May 13, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare, the leader and innovator in total talent solutions for healthcare organizations, announced the election of Eric Palmer to its Board of Directors, effective May 1 [...]
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
13/05/2026
First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- [...]
USOSM Secures Partnership with Hudson Valley Oral Surgery
13/05/2026
IRVING, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial surgeons –has secured a new partnership [...]
Noted Vaccine Researchers Uğur Şahin and Özlem Türeci Awarded Sabin Vaccine Institute’s Albert B. Sabin Gold Medal; Genomic Scientist Senjuti Saha of Bangladesh Receives Rising Star Award
13/05/2026
WASHINGTON, May 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Sabin Awards were presented yesterday at the National Academy of Sciences building in Washington, D.C., with Professor Uğur Şahin, MD, and Professor Özlem Türeci, MD [...]
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
13/05/2026
Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Neomorph Appoints Biopharma Leader Robert J. Hugin as Chairman of the Board
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc. , a biotechnology company advancing a new class of molecular glue degraders to target historically undruggable proteins, today announced the appointment of Bob [...]

Pages